Innocrin
is a pharmaceutical company that discovers and develops oral inhibitors for the treatment of castration-resistant prostate cancer... Read moreInnocrin
is a pharmaceutical company that discovers and develops oral inhibitors for the treatment of castration-resistant prostate cancer... Read more
News
Jul 13, 2017
The Business Journals
Innocrin: RTP pharma helmed by PPD founder Eshelman raises $6M
Jul 10, 2017
sec.gov
Innocrin: Innocrin Pharmaceuticals received $6M in Debt Funding
Jun 21, 2017
WRAL TechWire
Innocrin: Eshelman, Hatteras backed Innocrin lands regulatory boost in Europe
Jun 20, 2017
BioPortfolio
Innocrin: Innocrin Pharmaceuticals Inc. Granted SME Status Designation by the European Medicines Agency
Dec 12, 2016
PharmiWeb
Innocrin: Innocrin Pharmaceuticals Presents Data from the Ongoing Phase 2 Trial of Seviteronel in Estrogen Receptor-positive or Triple-negative Breast Cancer (CLARITY-01) at the San Antonio Breast Cancer Symposium
May 13, 2016
Pharmaceutical Business Review
Innocrin: Innocrin starts phase 2 study of Seviteronel in women with estrogen receptor-positive or triple-negative breast cancer
Jan 07, 2016
Pharamceutical Technology
Innocrin:
FDA grants fast-track status for Innocrin's seviteronel to treat metastatic CRPC
Jan 05, 2016
BioPortfolio
Innocrin: Innocrin Pharmaceuticals Inc. Granted Fast Track Designation by FDA for VT464 Treatment of Patients with Metastatic Castrateresistant Prostate Cancer
Jul 02, 2015
cfomoves
Innocrin: CFO Moves - week ending July 3, 2015
Jul 01, 2015
BIOSPACE
Innocrin: Innocrin Appoints As Its Chief Financial Officer
Innocrin Competitors
1
2
3
4
5
6
7
8
9
10